Cemiplimab Plus Chemotherapy Could Be a First-Line Option for Advanced and Metastatic NSCLC: Results From the Phase 3 EMPOWER-Lung 3 Part 2 Trial

J Thorac Oncol. 2023 Jul;18(7):e72-e73. doi: 10.1016/j.jtho.2023.04.001.
No abstract available

Publication types

  • Clinical Trial, Phase III
  • Letter
  • Comment

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • Carcinoma, Non-Small-Cell Lung* / pathology
  • Humans
  • Lung / pathology
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / pathology

Substances

  • Antibodies, Monoclonal, Humanized
  • cemiplimab

Associated data

  • ClinicalTrials.gov/NCT03409614